Albany Molecular Research, Inc. (NASDAQ:AMRI) Stake Boosted by Keybank National Association OH

Keybank National Association OH raised its holdings in Albany Molecular Research, Inc. (NASDAQ:AMRI) by 10.7% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 38,263 shares of the biotechnology company’s stock after buying an additional 3,711 shares during the quarter. Keybank National Association OH owned 0.09% of Albany Molecular Research worth $830,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Arizona State Retirement System grew its holdings in Albany Molecular Research by 0.9% in the 1st quarter. Arizona State Retirement System now owns 11,586 shares of the biotechnology company’s stock valued at $163,000 after buying an additional 100 shares during the last quarter. Texas Permanent School Fund grew its holdings in shares of Albany Molecular Research by 0.9% during the 2nd quarter. Texas Permanent School Fund now owns 16,299 shares of the biotechnology company’s stock worth $354,000 after purchasing an additional 151 shares in the last quarter. Teachers Advisors LLC grew its holdings in shares of Albany Molecular Research by 0.5% during the 4th quarter. Teachers Advisors LLC now owns 41,916 shares of the biotechnology company’s stock worth $786,000 after purchasing an additional 198 shares in the last quarter. Sii Investments Inc. WI grew its holdings in shares of Albany Molecular Research by 2.2% during the 1st quarter. Sii Investments Inc. WI now owns 11,460 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 250 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan grew its holdings in shares of Albany Molecular Research by 5.8% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 5,260 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 290 shares in the last quarter. 72.10% of the stock is currently owned by hedge funds and other institutional investors.

Albany Molecular Research, Inc. (NASDAQ AMRI) opened at 21.74 on Friday. The company’s 50 day moving average price is $21.72 and its 200 day moving average price is $18.41. The company’s market cap is $905.82 million. Albany Molecular Research, Inc. has a 52-week low of $13.01 and a 52-week high of $22.17.

AMRI has been the topic of several recent research reports. William Blair lowered Albany Molecular Research from an “outperform” rating to a “market perform” rating in a report on Tuesday, June 6th. J P Morgan Chase & Co lowered Albany Molecular Research from an “overweight” rating to a “neutral” rating in a report on Thursday, June 8th. First Analysis lowered Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a report on Monday, June 12th. Finally, BidaskClub downgraded Albany Molecular Research from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. Five investment analysts have rated the stock with a hold rating, The stock has an average rating of “Hold” and an average target price of $18.00.

ILLEGAL ACTIVITY WARNING: “Albany Molecular Research, Inc. (NASDAQ:AMRI) Stake Boosted by Keybank National Association OH” was reported by BBNS and is owned by of BBNS. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://baseballnewssource.com/markets/keybank-national-association-oh-grows-holdings-in-albany-molecular-research-inc-amri/1600694.html.

Albany Molecular Research Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with our FREE daily email newsletter.

 


Latest News

American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22


Leave a Reply

 
© 2006-2017 BBNS.